Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Colonization factor antigen I fimbria (CFA-I) is a filamentous surface structure expressed by enterotoxigenic Escherichia coli (ETEC). It belongs to the class of adhesive pili/fimbriae that mediate initial attachment of bacteria to human small intestinal epithelial cells—a critical first step in establishing infection and delivering toxins that cause diarrheal disease. Structurally, each pilus consists mainly of repeating CfaB subunits arranged into long helical filaments approximately 8 nm in diameter and up to several micrometers long; these filaments can adopt both helical and extended conformations depending on environmental conditions. The distal tip contains an adhesin subunit responsible for binding specific receptors on host cells. CFA-I expression enables efficient colonization under physiological conditions where peristalsis would otherwise remove non-adherent bacteria from the gut lumen. Its presence correlates strongly with pathogenicity among human-infecting ETEC strains, making it a major focus for vaccine development efforts aimed at preventing traveler’s diarrhea and childhood morbidity due to ETEC infections worldwide. Immunological studies show that humans mount antibody responses against this antigen during natural infection, supporting its relevance as both a diagnostic marker in research settings and as an immunogen in candidate vaccines.
Vaccines or antibodies targeting CFA-I aim to: - Block bacterial adhesion to intestinal mucosa, preventing colonization and subsequent toxin-mediated diarrhea. - Induce immune responses that neutralize the fimbrial structure or its adhesive tip subunit.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Colonization factor antigen I fimbria (CFA-I).